Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Superficial Basal Cell Carcinoma

Interventions

COMBINATION_PRODUCT: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
COMBINATION_PRODUCT: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

Sponsor

Biofrontera Inc.